Maplight Therapeutics (NASDAQ:MPLT) Insider James Woodruff Lillie Sells 24,811 Shares

Maplight Therapeutics, Inc. (NASDAQ:MPLT) insider James Woodruff Lillie sold 24,811 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $28.76, for a total value of $713,564.36. Following the transaction, the insider owned 243,450 shares of the company’s stock, valued at $7,001,622. This represents a 9.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Woodruff Lillie also recently made the following trade(s):

• On Tuesday, May 5th, James Woodruff Lillie sold 11,095 shares of Maplight Therapeutics stock. The shares were sold at an average price of $28.20, for a total transaction of $312,879.00.
• On Monday, May 4th, James Woodruff Lillie sold 15,801 shares of Maplight Therapeutics stock. The stock was sold at an average price of $27.96, for a total value of $441,795.96.

Maplight Therapeutics Trading Up 4.0%

NASDAQ MPLT traded up $1.12 during trading hours on Wednesday, hitting $29.04. 267,979 shares of the company were exchanged, compared to its average volume of 342,018. The stock has a 50-day moving average price of $22.60. Maplight Therapeutics, Inc. has a 52 week low of $12.24 and a 52 week high of $33.28. The stock has a market capitalization of $1.24 billion and a PE ratio of -0.73.

Maplight Therapeutics (NASDAQ:MPLT) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($2.47) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($1.42). As a group, analysts expect that Maplight Therapeutics, Inc. will post -3.96 EPS for the current year.

Key Maplight Therapeutics News

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: Needham reaffirmed its “Buy” rating on MPLT, signaling continued analyst conviction that the shares have upside. Needham Reaffirms Buy
• Positive Sentiment: HC Wainwright initiated/updated coverage with a “Buy” rating and a $45 price target (roughly mid‑50% upside from recent levels), which can attract buyers and support the rally. Many outlets reported the new coverage and target. HC Wainwright Coverage & Target
• Neutral Sentiment: Morningstar and market quote pages show current trading context (price, volume, 50‑day moving average) that traders use to gauge technical support/resistance. Use these pages for up‑to‑date quotes. Morningstar Quote
• Negative Sentiment: HC Wainwright’s detailed forecasts also project larger net losses over 2026–2027 (FY2026 EPS ~ -$4.34; FY2027 EPS ~ -$5.25) and quarterly losses through 2027 — data that underscores continued cash‑burn and execution risk for a clinical‑stage biotech. This raises downside risk if clinical or financing progress stalls. Analyst Estimates
• Negative Sentiment: Recent reported results included a sizable Q1 EPS miss (reported -$2.47 vs. consensus -$1.05), which remains a reminder of earnings volatility and could pressure sentiment if follow‑up data or guidance are weak. Recent Earnings Miss

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. TD Cowen assumed coverage on Maplight Therapeutics in a research report on Tuesday, April 7th. They set a “buy” rating for the company. HC Wainwright assumed coverage on Maplight Therapeutics in a research report on Monday. They set a “buy” rating and a $45.00 target price for the company. Wall Street Zen lowered Maplight Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Needham & Company LLC initiated coverage on Maplight Therapeutics in a report on Wednesday, April 8th. They issued a “buy” rating and a $37.00 price target for the company. Finally, Weiss Ratings initiated coverage on Maplight Therapeutics in a report on Thursday, January 22nd. They issued a “sell (e)” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.43.

Institutional Trading of Maplight Therapeutics

A number of large investors have recently modified their holdings of MPLT. Strs Ohio purchased a new stake in Maplight Therapeutics during the fourth quarter worth $53,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in Maplight Therapeutics during the fourth quarter worth $70,000. New York State Common Retirement Fund purchased a new stake in Maplight Therapeutics during the fourth quarter worth $93,000. MetLife Investment Management LLC purchased a new stake in Maplight Therapeutics during the fourth quarter worth $172,000. Finally, Walleye Capital LLC purchased a new stake in Maplight Therapeutics during the fourth quarter worth $205,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.